Lajos Pusztai, MD, DPhil

home / authors / lajos-pusztai-md-dphil

Articles

20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Erika P. Hamilton, MD;Lajos Pusztai, MD, DPhil;Hatem Soliman, MD;Sara A. Hurvitz, MD;Krzysztof J. Grzegorzewski;Nassir Habboubi;Priya Marreddy;Tarek Sahmoud, MD;Nuhad Ibrahim, MD

April 28th 2023

31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy

Aditya Bardia, MD, MPH;Lajos Pusztai, MD, DPhil;Kathy S. Albain, MD;Kevin Kalinsky, MD, MS;Dawn Herman;William Barlow;Claudine Isaacs, MD;Micah Maxwell;Nadia Harbeck, MD, PhD;Priyanka Sharma, MD

April 27th 2023

13 Assessing Intratumor Heterogeneity in Programmed Death-Ligand 1 (PD-L1) Protein Expression in Early-Stage Breast Cancer

Adriana Matutino Kahn;Reza Golestani;Malini Harigopal;Lajos Pusztai, MD, DPhil

April 18th 2022

New Therapeutic Strategies for Triple-Negative Breast Cancer

Borbála Székely, MD;Andrea L. M. Silber, MD;Lajos Pusztai, MD, DPhil

February 15th 2017

Relatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer since the introduction of taxanes as adjuvant therapy over 20 years ago. However, this is rapidly changing due to a variety of conceptually important clinical trials and emerging new options.

Commentary (Esteva/Pusztai)-Optimizing Outcomes in HER2-Positive Breast Cancer: The Molecular Rationale

Francisco J. Esteva, MD, PhD;Lajos Pusztai, MD, DPhil

November 1st 2005

The selective activity and demonstratedsafety of targetedtherapies has generated newhope for improving the treatment ofpatients with cancer.

Optimizing Outcomes in HER2-Positive Breast Cancer: The Molecular Rationale

Francisco J. Esteva, MD, PhD;Lajos Pusztai, MD, DPhil

November 1st 2005

The epidermal growth factor (EGF) receptor HER2 is a transmembranereceptor tyrosine kinase that plays a crucial role in the regulationof cell proliferation and survival. The overexpression of HER2correlates strongly with prognosis in breast cancer. The targeted blockadeof HER2 activity with monoclonal antibodies (eg, trastuzumab[Herceptin]) and small-molecule tyrosine kinase inhibitors (eg,lapatinib) results in the inhibition of tumor growth in HER2-positivecancers. Anti-HER2 therapies have also shown efficacy in combinationwith chemotherapy in clinical trials in patients with HER2-positive breast cancer. Their efficacy may, however, be limited bymolecular mechanisms that compensate for HER2 suppression (eg,activity of EGF receptor) or mechanisms of resistance (eg, loss ofPTEN). HER2 continues, however, to be overexpressed by the cancercells, and the continued suppression of HER2 may be required formaximum antitumor effect. It should be noted that in the absence ofdefinitive data from randomized trials showing an absence or presenceof benefit, the use of anti-HER2 agents such as trastuzumab in multiplesequential regimens has become the standard of care. CombiningHER2 blockers with agents that overcome the compensatory or resistancemechanisms may increase the efficacy of anti-HER2 therapies.In addition, anti-HER2 therapies can have synergy with common chemotherapyregimens and remain effective through multiple lines oftherapy. Optimizing the use of therapies that target HER2 signalingwill lead to further advances in the treatment of breast cancer.